- Home
- DMAC vs SCD Comparison
DMAC vs SCD Comparison
Compare DMAC & SCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- SCD
- Stock Information
- Founded
- DMAC 2000
- SCD 2003
- Country
- DMAC United States
- SCD United States
- Employees
- DMAC N/A
- SCD N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- SCD Trusts Except Educational Religious and Charitable
- Sector
- DMAC Health Care
- SCD Finance
- Exchange
- DMAC Nasdaq
- SCD Nasdaq
- Market Cap
- DMAC 310.1M
- SCD 264.7M
- IPO Year
- DMAC N/A
- SCD N/A
- Fundamental
- Price
- DMAC $6.87
- SCD $15.78
- Analyst Decision
- DMAC Strong Buy
- SCD
- Analyst Count
- DMAC 3
- SCD 0
- Target Price
- DMAC $12.33
- SCD N/A
- AVG Volume (30 Days)
- DMAC 448.5K
- SCD 62.6K
- Earning Date
- DMAC 11-12-2025
- SCD 01-01-0001
- Dividend Yield
- DMAC N/A
- SCD 9.63%
- EPS Growth
- DMAC N/A
- SCD N/A
- EPS
- DMAC N/A
- SCD N/A
- Revenue
- DMAC N/A
- SCD N/A
- Revenue This Year
- DMAC N/A
- SCD N/A
- Revenue Next Year
- DMAC N/A
- SCD N/A
- P/E Ratio
- DMAC N/A
- SCD N/A
- Revenue Growth
- DMAC N/A
- SCD N/A
- 52 Week Low
- DMAC $3.19
- SCD $11.33
- 52 Week High
- DMAC $7.49
- SCD $15.87
- Technical
- Relative Strength Index (RSI)
- DMAC 63.84
- SCD 70.53
- Support Level
- DMAC $6.83
- SCD $15.36
- Resistance Level
- DMAC $7.41
- SCD $15.59
- Average True Range (ATR)
- DMAC 0.43
- SCD 0.11
- MACD
- DMAC 0.03
- SCD 0.04
- Stochastic Oscillator
- DMAC 73.62
- SCD 83.50
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.